|Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer|
NA Rizvi, MD Hellmann, A Snyder, P Kvistborg, V Makarov, JJ Havel, ...
Science 348 (6230), 124-128, 2015
|Pembrolizumab for the treatment of non–small-cell lung cancer|
EB Garon, NA Rizvi, R Hui, N Leighl, AS Balmanoukian, JP Eder, ...
New England Journal of Medicine 372 (21), 2018-2028, 2015
|Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors|
B Routy, E Le Chatelier, L Derosa, CPM Duong, MT Alou, R Daillère, ...
Science 359 (6371), 91-97, 2018
|Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade|
N McGranahan, AJS Furness, R Rosenthal, S Ramskov, R Lyngaa, ...
Science 351 (6280), 1463-1469, 2016
|Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden|
MD Hellmann, TE Ciuleanu, A Pluzanski, JS Lee, GA Otterson, ...
New England Journal of Medicine 378 (22), 2093-2104, 2018
|Immune-related adverse events associated with immune checkpoint blockade|
MA Postow, R Sidlow, MD Hellmann
New England Journal of Medicine 378 (2), 158-168, 2018
|Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients|
A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ...
Nature medicine 23 (6), 703, 2017
|Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer|
SN Gettinger, L Horn, L Gandhi, DR Spigel, SJ Antonia, NA Rizvi, ...
Journal of clinical oncology 33 (18), 2004, 2015
|Tumor mutational load predicts survival after immunotherapy across multiple cancer types|
RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ...
Nature genetics 51 (2), 202-206, 2019
|Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up|
D Planchard, S Popat, K Kerr, S Novello, EF Smit, C Faivre-Finn, TS Mok, ...
Annals of Oncology 29, iv192-iv237, 2018
|Neoadjuvant PD-1 blockade in resectable lung cancer|
PM Forde, JE Chaft, KN Smith, V Anagnostou, TR Cottrell, MD Hellmann, ...
New England Journal of Medicine 378 (21), 1976-1986, 2018
|OncoKB: a precision oncology knowledge base|
D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ...
JCO precision oncology 1, 1-16, 2017
|Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study|
MD Hellmann, NA Rizvi, JW Goldman, SN Gettinger, H Borghaei, ...
The lancet oncology 18 (1), 31-41, 2017
|Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled …|
H Rizvi, F Sanchez-Vega, K La, W Chatila, P Jonsson, D Halpenny, ...
Journal of Clinical Oncology 36 (7), 633, 2018
|Nivolumab plus ipilimumab in advanced non–small-cell lung cancer|
MD Hellmann, L Paz-Ares, R Bernabe Caro, B Zurawski, SW Kim, ...
New England Journal of Medicine 381 (21), 2020-2031, 2019
|Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy|
J Naidoo, X Wang, KM Woo, T Iyriboz, D Halpenny, J Cunningham, ...
Journal of Clinical Oncology 35 (7), 709, 2017
|STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma|
F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ...
Cancer discovery 8 (7), 822-835, 2018
|Nivolumab versus docetaxel in previously treated patients with advanced non–small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials …|
L Horn, DR Spigel, EE Vokes, E Holgado, N Ready, M Steins, ...
Journal of clinical oncology 35 (35), 3924, 2017
|Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma|
D Miao, CA Margolis, W Gao, MH Voss, W Li, DJ Martini, C Norton, ...
Science 359 (6377), 801-806, 2018
|Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer|
MD Hellmann, MK Callahan, MM Awad, E Calvo, PA Ascierto, A Atmaca, ...
Cancer cell 33 (5), 853-861. e4, 2018